Effect of aspirin on all-cause mortality in the healthy elderly

New England Journal of Medicine

Volumn 379, Issue 16, 2018, Pages 1519-1528

  McNeil, J J ^a   Nelson, M R ^a,e   Woods, R L ^a   Lockery, J E ^a   Wolfe, R ^a   Reid, C M ^a,f   Kirpach, B ^j   Shah, R C ⁿ   Ives, D G ^o   Storey, E ^a   Ryan, J ^a   Tonkin, A M ^a   Newman, A B ^o   Williamson, J D ^p   Margolis, K L ^l   Ernst, M E ^q   Abhayaratna, W P ^h   Stocks, N ⁱ   Fitzgerald, S M ^a   Orchard, S G ^a   Trevaks, R E ^a   Beilin, L J ^g   Donnan, G A ^d   Gibbs, P ^b   Johnston, C I ^a,c   Radziszewska, B ^r   Grimm, R ^j   Murray, A M ^j,k,m   more..

^a MONASH UNIVERSITY   (Australia)

^b WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e UNIVERSITY OF TASMANIA   (Australia)

^f CURTIN UNIVERSITY   (Australia)

^g ROYAL PERTH HOSPITAL   (Australia)

^h AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

ⁱ UNIVERSITY OF ADELAIDE   (Australia)

^j HENNEPIN HEALTHCARE RESEARCH INSTITUTE   (United States)

^k Div of Geriatrics   (United States)

^l HEALTHPARTNERS INSTITUTE   (United States)

^m UNIVERSITY OF MINNESOTA   (United States)

ⁿ RUSH UNIVERSITY MEDICAL CENTER   (United States)

^o UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^p WAKE FOREST SCHOOL OF MEDICINE   (United States)

^q UNIVERSITY OF IOWA   (United States)

^r NATIONAL INSTITUTE ON AGING   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; PLACEBO; ANTITHROMBOCYTIC AGENT;

AGE; AGED; ALL CAUSE MORTALITY; ARTICLE; AUSTRALIA; BLACK PERSON; CANCER MORTALITY; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; COMMUNITY DWELLING PERSON; DEMENTIA; DISABILITY; DRUG EFFECT; DRUG USE; ELDERLY CARE; FEMALE; FOLLOW UP; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY RISK; OUTCOME ASSESSMENT; POST HOC ANALYSIS; PRIORITY JOURNAL; UNITED STATES; BLEEDING; CHEMICALLY INDUCED; CLINICAL TRIAL; CONTROLLED STUDY; INDEPENDENT LIVING; MORTALITY; MULTICENTER STUDY; NEOPLASM; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; VERY ELDERLY;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ASPIRIN; AUSTRALIA; CAUSE OF DEATH; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; INDEPENDENT LIVING; MALE; MORTALITY; NEOPLASMS; PLATELET AGGREGATION INHIBITORS; TREATMENT FAILURE; UNITED STATES;

EID: 85054966244     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1803955     Document Type: Article

References (21)

1. McNeil JJ, Woods RL, Nelson MR, et al. Effect of aspirin on disability-free survival in the healthy elderly. N Engl J Med 2018;379:1499-508.
2. McNeil JJ, Wolfe R, Woods RL, et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med 2018;379:1509-18.
3. Ikeda Y, Shimada K, Teramoto T, et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA 2014; 312: 2510-20.
4. Fowkes FGR, Price JF, Stewart MCW, et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 2010; 303: 841-8.
5. Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008; 300: 2134-41.
6. Belch J, MacCuish A, Campbell I, et al. The Prevention of Progression of Arterial Disease and Diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008; 337: a1840.
7. Ridker PM, Cook NR, Lee I-M, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352: 1293-304.
8. de Gaetano G. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 2001; 357: 89-95.
9. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-62.
10. The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998; 351: 233-41.
11. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the on going Physicians' Health Study. N Engl J Med 1989; 321: 129-35.
12. Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 1988; 296: 313-6.
13. ASPREE Investigator Group. Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial. Contemp Clin Trials 2013; 36: 555-64.
14. The Ryerson Index home page (https://www.ryersonindex.org/).
15. Wolfe R, Murray AM, Woods RL, et al. The ASPirin in Reducing Events in the Elderly trial: statistical analysis plan. Int J Stroke 2018; 13: 335-8.
16. Andersen PK, Geskus RB, de Witte T, Putter H. Competing risks in epidemiology: possibilities and pitfalls. Int J Epidemiol 2012; 41: 861-70.
17. McNeil JJ, Woods RL, Nelson MR, et al. Baseline characteristics of participants in the ASPREE (ASPirin in Reducing Events in the Elderly) study. J Gerontol A Biol Sci Med Sci 2017; 72: 1586-93.
18. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 2007; 356: 2131-42.
19. Rothwell PM, Fowkes FGR, Belch JFF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011; 377: 31-41.
20. Rothwell PM, Wilson M, Price JF, Belch JFF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012; 379: 1591-601.
21. Drew DA, Cao Y, Chan AT. Aspirin and colorectal cancer: the promise of precision chemoprevention. Nat Rev Cancer 2016; 16: 173-86.